India, Sept. 15 -- image credit- freepik

Hyderabad-based Dr. Reddy's Laboratories has announced the launch of NIVORZ(R) (Nivolumab Biosimilar) in India. NIVORZ(R) is a biosimilar to Opdivo(R) (nivolumab), a fully human monoclonal antibody that targets the PD-1 (Programmed Death-1) immune checkpoint, helping restore the immune system's ability to identify and fight cancer cells.

The launch represents a significant milestone for Dr. Reddy's, with NIVORZ(R) marking its entry into biosimilar immuno-oncology in India. Developed and manufactured entirely in-house at Dr. Reddy's biologics facility in Bachupally, Hyderabad, it reflects the company's end-to-end capabilities across the biosimilar value chain, from development through commercialis...